Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that initiate primary immune responses. 1,2 DCs are distinguished from B lymphocytes and macrophages by their abundant expression of major histocompatibility complex (MHC) class I, class II, costimulatory molecules, and adhesion molecules, which provide secondary signals for the stimulation of naive T-cell populations. [3] [4] [5] In addition, DCs have the ability to efficiently prime both CD8 ϩ and CD4 ϩ immunity. 6 On the basis of these findings, antitumor vaccines have been developed with DCs that have been pulsed, transfected, or transduced to present peptides derived from tumor antigens. [7] [8] [9] [10] [11] [12] These approaches require a known tumor antigen, and few at present have been identified for human tumors.
Introduction
Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that initiate primary immune responses. 1, 2 DCs are distinguished from B lymphocytes and macrophages by their abundant expression of major histocompatibility complex (MHC) class I, class II, costimulatory molecules, and adhesion molecules, which provide secondary signals for the stimulation of naive T-cell populations. [3] [4] [5] In addition, DCs have the ability to efficiently prime both CD8 ϩ and CD4 ϩ immunity. 6 On the basis of these findings, antitumor vaccines have been developed with DCs that have been pulsed, transfected, or transduced to present peptides derived from tumor antigens. [7] [8] [9] [10] [11] [12] These approaches require a known tumor antigen, and few at present have been identified for human tumors.
As an approach to exploit both known and unidentified tumor epitopes, DCs have been fused to cancer cells to generate heterokaryons that combine the expression of molecules needed for immune stimulation with presentation of a potential repertoire of tumor antigens. 13 Vaccination with fusions of murine tumor cells and syngeneic DCs has been shown to eliminate established metastatic disease in diverse models. [13] [14] [15] [16] [17] This approach has also been extended to the fusion of human tumor cells with autologous and allogeneic DCs. 18, 19 The human fusions were effective in stimulating cytotoxic T-lymphocyte (CTL) responses against autologous tumors. 18, 19 Moreover, vaccination with tumor-DC fusions has been successful in the treatment of patients with metastatic renal cell carcinoma. 20 Interleukin 12 (IL-12) is a heterodimeric cytokine that upregulates DC expression of costimulatory molecules. 21, 22 IL-12 induces stimulation of Th1 reactivity. 23 Other studies have shown that IL-12 inhibits induction of anergy, reverses immunologic unresponsiveness to tumor antigens, and expands antigen-specific CD8 ϩ T cells. 12, [24] [25] [26] In concert with these findings, IL-12 was found to be necessary for the rejection of tumors in mice and to improve the efficacy of antitumor vaccines using peptide-pulsed DCs 27, 28 and RNA-transfected DCs. 12 In the present study, we describe a fusion cell vaccine for the treatment of a mouse model of multiple myeloma. The results demonstrate that the vaccine is effective in prolonging the survival of mice with established disease. We also show that, when combined with IL-12, the fusion cell vaccine is effective in the long-term eradication of multiple myeloma.
Materials and methods

Cell culture and fusion
Murine Balb/c plasmacytoma 4TOO, 29 murine Balb/c MPC-11, and human SKO-007 myeloma cells (American Type Culture Collection [ATCC], Manassas, VA) were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin. Syngeneic DCs were generated from the bone marrow of Balb/c mice by culture in 20 ng/mL granulocytemacrophage colony-stimulating factor (Sigma, St Louis, MO) for 5 days as described. 13, 30 The DCs were fused with 4TOO cells (FC/4TOO) at a 10:1 ratio in the presence of 50% polyethylene glycol (Sigma) as described. 13, 30 The FC/4TOO cells were then selected in hypoxanthine-aminopterinthymidine (HAT) medium (Sigma) for 5 to 8 days.
Flow cytometry
To quantitate the DC/4TOO fusion cells, 4TOO cells were stained with the red fluorescence dye PKH-26 (Sigma), washed with phosphate-buffered saline (PBS), and then fused with DCs. DCs, PKH-26-labeled 4TOO cells, and FC/4TOO cells were incubated with monoclonal antibody (MAb) M1/42/3.9.8 (anti-MHC class I; ATCC), MAb anti-M5/114 (anti-MHC class II), MAb 16-10A1 (anti-CD80), or MAb GL1 (anti-CD86) (Pharmingen, San Diego, CA) for 30 minutes on ice. After washing with PBS, the cells were incubated with the appropriate fluorescein isothiocyanateconjugated antihamster, antirat, or antimouse immunoglobulin G (IgG) for another 30 minutes on ice. Samples were then washed, fixed, and analyzed by FACScan (Becton Dickinson, Bedford, MA). For dual staining, cells were incubated with anti-Syndecan-1 (anti-CD138; Pharmingen) for 30 minutes at 4°C and then with fluorescein isothiocyanate-conjugated goat antimouse IgG. The cells were washed and then incubated with phycoerythrin-conjugated anti-MHC class II for 30 minutes at 4°C. After washing again, cells were fixed with 2% paraformaldehyde and subjected to bidimensional FACScan and analysis using Cellquest software.
Mixed lymphocyte reactions
DCs, 4TOO cells, and FC/4TOO cells were irradiated (30 Gy) and incubated at the indicated ratios with allogeneic (C57BL/6) T cells in 96-well U-bottom plates for 5 days. The T cells were prepared as described. 13 Proliferation of T cells was assessed by pulsing with 0.037 MBq (1 Ci)/well [ 3 H]-thymidine (New England Nuclear, Boston, MA) for 12 hours and monitoring for tritium incorporation.
Humoral immune responses
Sera were obtained from mice at 7 days after the second immunization. Microtiter plates were precoated with 4TOO, MPC-11, or SKO-007 cell lysate by incubation overnight at 4°C. The wells were washed and incubated with a 4-fold dilution of mouse sera for 1 hour at 4°C. After washing and incubation with goat antimouse IgG conjugated to horseradish peroxidase (Amersham, Piscataway, NJ), the antibody complexes were detected by development with o-phenylenediamine (Sigma) and measured in an enzyme-linked immunosorbent assay microplate autoreader EL 310 at 490 nm.
Cytotoxicity assays
4TOO, MPC-11, and SKO-007 cell targets were labeled with 51 Cr for 60 minutes at 37°C, added to 96-well v-bottom plates, and incubated with splenocytes from the immunized mice for 5 hours at 37°C. The culture supernatants were assayed in a gamma counter. Spontaneous release of 51 Cr was assessed by incubation of targets in the absence of splenocytes. Maximum or total 51 Cr release was determined by incubation of targets in 0.1% Triton X-100. Percentage of specific 51 Cr release was determined by the equation: percentage of specific release ϭ [(experimental Ϫ spontaneous)/(maximum Ϫ spontaneous)] ϫ 100.
T-cell proliferation assay
Lymph node cells (LNCs) and splenocytes from immunized mice were prepared as single cell suspensions. Erythrocytes and dead cells were removed by centrifugation into a Ficoll-Hypaque gradient. LNCs and splenocytes were washed and resuspended in RPMI-1640 medium supplemented with 15 mM HEPES (pH 7.4), 5% HI-FCS, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 100 U/mL penicillin, 100 g/mL streptomycin, and 5 ϫ 10 5 ␤-mercaptoethanol. Cells were incubated with irradiated FC/4TOO cells at a 10:1 ratio in 96-well, U-bottom plates for 5 days. Cell proliferation was assessed by [ 3 H]thymidine incorporation after an additional 12-hour incubation.
Mouse IL-12 production and assay
Recombinant mouse IL-12 (rmIL-12) was prepared from the culture supernatants of SP2/O cells transfected to stably express the p35 and p40 subunits (kindly provided by Dr Knight, Centocor). Production of IL-10 and IL-12 by DCs, 4TOO cells, and FC/4TOO cells was measured by the mouse IL-10 and IL-12 OptEIA enzyme-linked immunosorbent assay kits (Pharmingen).
Antitumor studies in vivo
Groups of 10 Balb/c mice were immunized twice subcutaneously with 10 6 DCs; irradiated 4TOO, DCs, and 4TOO that had been coincubated for 24 hours (not fused); or FC/4TOO cells on days 0 and 7. On day 14, the mice were challenged intravenously with 2 ϫ 10 5 4TOO plasmacytoma cells. In the treatment studies, Balb/c mice were injected intravenously with 2 ϫ 10 5 4TOO plasmacytoma cells on day 0. On days 2, 6, and 10, the mice were treated intravenously with 1 ϫ 10, 6 2 ϫ 10 6 , or 5 ϫ 10 6 FC/4TOO cells. rmIL-12 was administered intraperitoneally. Irradiated 4TOO cells were used as controls.
Results
Fusion of 4TOO plasmacytoma cells and DCs
Murine Balb/c plasmacytoma 4TOO cells were fused to syngeneic bone marrow-derived DCs in the presence of polyethylene glycol. To assess the formation of heterokaryons, the cells were cultured for 7 days and then analyzed for expression of surface markers selective for the fusion cell population. Red fluorescence from staining with PKH-26 was detectable on the surface of 4TOO cells but not on DCs ( Figure 1A ). By contrast, MHC class II, CD80, and CD86 were expressed by DCs and not by 4TOO cells ( Figure 1A ). MHC class I was detectable on both 4TOO cells and DCs ( Figure  1A ). In concert with the formation of heterokaryons, MHC class II, CD80, and CD86 were detectable on the FC/4TOO fusion cells ( Figure 1A ). Moreover, detection of red fluorescence and MHC For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From class II, CD80, and CD86 confirmed the formation of heterokaryons ( Figure 1A ). On the basis of the findings, the fusion efficiency was between 30% and 50%. To confirm these findings, 4TOO, DCs, and FC/400 cells were analyzed by bidimensional flow cytometry for reactivity with antibodies against MHC class II and Syndecan, an antigen expressed by myeloma cells. 31 The results demonstrate that, in contrast to DCs and 4TOO cells, more than 50% of the FC/4TOO cell population expressed both MHC class II and Syndecan ( Figure 1B ). To characterize in part the function of FC/4TOO cells, we compared their activity with 4TOO cells or DCs as stimulators in primary allogeneic mixed lymphocyte reactions. The 4TOO cells had little effect on T-cell proliferation ( Figure 1C ). By contrast, FC/4TOO cells, like DCs, stimulated proliferation of the allogeneic T cells ( Figure 1C ). These findings demonstrate that the FC/4TOO cells, which express MHC and costimulatory molecules, are functional in mixed lymphocyte reactions.
Induction of immunity with FC/4TOO cells
To assess whether immunization with FC/4TOO cells induces an anti-4TOO immune response, mice were vaccinated subcutaneously twice with 1 ϫ 10 6 irradiated DCs, 4TOO cells, or FC/4TOO cells. In contrast to DCs, immunization with 4TOO or FC/4TOO cells resulted in induction of anti-4TOO antibody responses (Figure 2A ). Immunization with FC/4TOO was also associated with induction of an antibody response against murine MPC-11 myeloma cells, but to a lesser extent than that obtained against 4TOO cells ( Figure 2B ). As a control, there was no detectable antibody response against human SKO-007 myeloma cells ( Figure  2B ). To assess cell-mediated immunity, splenocytes from the immunized mice were analyzed for CTL activity against 4TOO cell targets. There was little, if any, lysis of 4TOO cells in the presence of splenocytes from mice immunized with DCs ( Figure 2C ). CTL activity was detectable in mice immunized with irradiated 4TOO cells, and this response was more pronounced in mice vaccinated with FC/4TOO cells ( Figure 2C ). As controls, CTL activity was detectable against MPC-11 but not SKO-007 cells ( Figure 2D ). These findings indicate that, like irradiated 4TOO cells, immunization with FC/4TOO is associated with induction of humoral and cell-mediated immune responses.
FC/4TOO cells induce antitumor activity
To assess the induction of antitumor immunity, mice were immunized with irradiated DCs, 4TOO cells, or FC/4TOO cells and then challenged intravenously with 2 ϫ 10 5 viable 4TOO cells. Mice vaccinated with DCs, 4TOO cells, or DCs coincubated with 4TOO cells rapidly succumbed to their disease at a rate similar to that found in control mice given PBS ( Figure 3A) . By contrast, 80% of the mice immunized with FC/4TOO cells were protected against tumor challenge ( Figure 3A) . In studies to assess treatment of established disease, mice were first given 2 ϫ 10 5 4TOO cells intravenously on day 0 and then treated with different doses of irradiated FC/4TOO cells on days 2, 6, and 10. Compared with mice immunized with 1 ϫ 10 6 irradiated 4TOO cells or DCs alone, those mice given 2 ϫ 10 5 FC/4TOO cells survived longer ( Figure  3B ). Moreover, treatment with higher doses of FC/4TOO cells was associated with progressively longer durations of survival ( Figure  3B ). CTL activity against 4TOO cells reached approximately 20% as a consequence of FC/4TOO vaccination and then decreased to background levels, as the mice succumbed to their disease. These results indicate that the antitumor immune response induced by FC/4TOO vaccination corresponds with disease course. Nonetheless, all mice treated with FC/4TOO succumbed to the tumor ( Figure 3B ). To determine whether a lower tumor burden can be eradicated, mice given 1 ϫ 10 5 tumor cells were treated with 2 ϫ 10 6 irradiated FC/4TOO cells. By using these experimental conditions, survival was extended, but all of the animals died of progressive disease ( Figure 3C ). These findings indicated that FC/4TOO immunization is effective only in part in inducing antitumor activity.
IL-12 potentiates FC/4TOO-induced T-cell responses
Whereas IL-12 improves the effectiveness of DC-based antitumor vaccines, 12 Figure  4C ). Similar findings were obtained when splenocytes were used as a source of CTLs ( Figure 4D ). These results demonstrate that IL-12 potentiates FC/4TOO-induced T-cell responses.
One potential explanation for IL-12-induced potentiation of FC/4TOO vaccination is that production of IL-12 by FC/4TOO is decreased as a consequence of fusing DCs with tumor cells. In this context, IL-10 is produced by certain tumors, and IL-10 suppresses IL-12 expression. 32, 33 To determine whether IL-10 affects IL-12 production by FC/4TOO cells, IL-10 and IL-12 levels were measured in culture supernatants. The results demonstrate that IL-10 levels are substantially higher than IL-12 levels in supernatants from 4TOO cells ( Table 1) . By contrast, DCs expressed lower levels of IL-10 and higher levels of IL-12 (Table 1) . Compared with 4TOO cells, IL-10 levels in the supernatants of FC/4TOO cells were also relatively low, and IL-12 levels were similar to those obtained with DCs (Table 1) . These findings and those obtained in vivo indicate that IL-12 potentiation of FC/4TOO-induced immunity is not a consequence of decreased IL-12 production by the fusion cells. The results (pg/mL) represent the mean ϩ SE of 3 determinations performed on supernatants obtained after culturing for 8 days. mIL, murine interleukin.
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IL-12 potentiates the FC/4TOO vaccine
To assess the role of IL-12 in the treatment of established disease, other experiments were performed in which 1 ϫ 10 6 4TOO cells were administered intravenously on day 0, and the mice were treated with FC/4TOO cells on days 2, 6, and 10. IL-12 (500 ng/mouse) was administered intraperitoneally after each vaccination to potentiate FC/ 4TOO-induced activation of T cells ( Figure 5A ). The results demonstrate that, at this high tumor innoculum, immunization with FC/4TOO cells had no effect on survival ( Figure 5A ). By contrast, treatment with FC/4TOO cells and 500 ng IL-12 resulted in 40% of the mice surviving for 300 days when the experiment was terminated ( Figure 5A and data not shown). The killed animals showed no evidence of disease. Other cohorts were killed on day 16 after immunization for analysis of CTL activity. Mice given IL-12 alone showed no evidence for induction of anti-4TOO activity ( Figure 5B) . Significantly, and in concert with the antitumor data, vaccination with FC/4TOO and IL-12 was more effective in inducing CTL activity as compared with that found with FC/4TOO alone ( Figure 5B ). To confirm these findings, treatment studies were performed in which FC/4TOO cells were administered with 200 ng IL-12/mouse. The results demonstrate that, under these experimental conditions, 50% of the mice survived 160 days when the experiment was terminated ( Figure 5C ). None of the surviving mice had evidence of disease. Other cohorts treated in this manner were killed for analysis of CTL activity. The results confirm that IL-12 potentiates the effects of FC/4TOO immunization on the induction of a CTL response against 4TOO cells ( Figure 5D ).
Discussion
Idiotype (Id) structures on the surface immunoglobulin of malignant clonal B cells represent potential tumor-specific antigens. Studies in animal models of multiple myeloma have identified both antibodies and T cells that exhibit specific recognition of the idiotypic antigen. Immunization with soluble Id ϩ immunoglobulin protects mice against subsequent challenge with Id ϩ , but not Id Ϫ , tumor cells. 34 Vaccine studies in patients with myeloma have also demonstrated the induction of anti-Id responses. [35] [36] [37] [38] [39] Thus, although Id epitopes represent myeloma-specific antigens, given the genomic instability associated with tumor progression, there are conceivably other epitopes that are unique to malignant B-cell clones. In the present studies, we have used a plasmacytoma-DC fusion cell vaccine to target unique epitopes and thereby the induction of a tumor-specific immune response. The results demonstrate the generation of heterokaryons that are functional as a vaccine in the stimulation of a humoral immune response against epitopes expressed by the plasmacytoma cells. The results also demonstrate that immunization with the FC/4TOO cells induce antitumor T-cell proliferative and CTL responses. The demonstration that immunization with FC/4TOO induces partial crossreactivity with MPC-11 myeloma cells supports the recognition of shared antigens that are probably not idiotypic. These findings thus support the induction of antimyeloma immune responses in the absence of a defined tumor antigen.
Tumor-DC fusion cell vaccines have been found to be effective in the treatment of established carcinomas, lymphomas, and melanomas in mice. [13] [14] [15] [16] [17] These findings have recently been extended to the treatment and long-term survival of patients with metastatic renal cell carcinoma. 20 The present results demonstrate that fusions of myeloma cells and DCs are effective in protecting mice against tumor challenge. In addition, treatment of established myeloma with the FC/4TOO cell vaccine was effective in prolonging survival. However, in contrast to the results obtained in other mouse tumor models, mice with established myeloma failed to respond to the vaccine with long-term survival. One potential explanation for these findings is that induction of a cell-mediated antitumor response, although detectable after immunization with the fusion cell vaccine, was insufficient to completely suppress growth of the malignant cells. In this context, fusions of certain types of tumor cells with DCs may result in heterokaryons that express the necessary MHC, costimulatory, and adhesion molecules, but not the requisite levels of cytokines needed for an optimal CTL response.
Previous work has demonstrated that IL-12 functions as a third signal, along with the T-cell receptor and costimulatory molecules, in reversing tolerance and expanding antigen-specific CD8 ϩ cells. 25, 26 Immunization with the FC/4TOO cell vaccine alone was effective, only in part, in extending survival of mice with established myeloma, whereas administration of FC/4TOO cells and IL-12 resulted in eradication of the disease. Antitumor CTL and T-cell proliferative responses induced by the FC/4TOO vaccine were also potentiated by coadministration of IL-12. Fusion cells track to paracortical areas of lymph nodes and form clusters with T cells. 33 The IL-12 was administered 2 days after each of 3 FC/4TOO vaccinations to increase IL-12 levels at a time when the fusion cells would potentially be activating T cells in regional lymph nodes. As activation and expansion of antigen-specific T cells is in part dependent on IL-12, 25,26 the level of IL-12 secretion by the fusion cells could define the magnitude of the CTL response. Our in vitro data indicate that FC/4TOO cells produce IL-12 at a level comparable to that of DCs. These findings, however, do not exclude the possibility that production of IL-12 by FC/4TOO cells in vivo is insufficient for optimal induction of an antitumor immune response. Indeed, the finding that systemic administration of IL-12 stimulates the effects of the FC/4TOO vaccine on induction of both CTL and antitumor activities provides support for insufficient local production of IL-12 by the fusion cells.
Multiple myeloma is typically incurable, even with myeloablative chemotherapy and stem cell transplantation. The findings of the present study present the first evidence for a vaccine that is effective in the treatment of established myeloma in the mouse. Given the limitations of animal models, immunization with myeloma-DC fusions may represent an effective approach for the treatment of myeloma in patients. In this context, fusions of human myeloma and autologous DCs have been prepared that are functional in the activation of autologous T cells. 40 The findings of the present work also support an immunization strategy in clinical trials that includes coadministration of IL-12.
